Sugi Predict

Sugi Predict / Compounds / SCHEMBL3797304

SCHEMBL3797304

SCHEMBL3797304

CC(C)(C)[Si](C)(C)Oc1cccc(Cl)c1-c1cc(-c2cncc(NC(=O)C(Cl)Cl)c2)on1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ POLB P06746 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ JAK3 P52333 1/20 0.34
▸ DOT1L Q8TEK3 1/20 0.34
▸ TP53 P04637 4/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CTSA P10619 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ MAPK14 Q16539 1/20 0.32
▸ TDP1 Q9NUW8 2/20 0.32
▸ KDR P35968 1/20 0.32
▸ CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3798740 0.87 MAPT (0.58) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL5335832 0.84 MAPT (0.46) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3801990 0.84 MAPT (0.46) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3803424 0.84 MAPT (0.52) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3797616 0.83 MAPT (0.51) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3799752 0.80 MAPT (0.47) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3796833 0.80 MAPT (0.41) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3802550 0.79 HTR2C (0.41) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL5153002 0.79 MAPT (0.64) MAPTKMT2AMEN1POLBKDM4E
SCHEMBL3801913 0.79 MAPT (0.45) MAPTKMT2AMEN1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714137-B2 2,2-Dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-(4-pyridyl)]Acetamide; Hepatitis C virus RIGEL PHARMACEUTICALS, INC. (US) 2010-05-11 — — US disclosed
US-20080171871-A1 Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection RIGEL PHARMACEUTICALS, INC. (US) 2008-07-17 — — US disclosed
US-7157473-B2 Pyridyl substituted heterocycles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2007-01-02 — — US disclosed
US-20040127497-A1 Pyridyl substituted heterocycles useful for treating or preventing HCV infection MIDCAP FINANCIAL TRUST 2004-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127497-A1 Pyridyl substituted heterocycles useful for treating or preventing HCV infection HAVCR2, HCCS, NQO1 MAPT 4676/4885KMT2A 3703/4885MEN1 4530/4885
US-20080171871-A1 Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection HAVCR2, HCCS, NQO1 MAPT 4676/4885KMT2A 3703/4885MEN1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.